Evidence map›Paper›PMID 38917692›Full record

ArticleVirology2024

Merkel Cell Polyomavirus targets SET/PP2A complex to promote cellular proliferation and migration.

Purnima Gupta, Assunta Venuti, Michelle Savoldy, Alexis Harold, Francesco A Zito, Valerio Taverniti, Maria Carmen Romero-Medina, Luisa Galati, Cecilia Sirand, Naveed Shahzad and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. EmergingFrontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Purnima GuptaInternational Agency for Research on Cancer, Lyon, France. Electronic address: purnimagupta1987@gmail.com.
Assunta VenutiInternational Agency for Research on Cancer, Lyon, France.
Michelle SavoldyCancer Virology Program, University of Pittsburgh, Pittsburgh, PA, USA.
Alexis HaroldCancer Virology Program, University of Pittsburgh, Pittsburgh, PA, USA.
Francesco A ZitoBari Dipartimento dei Servizi, U.O.C. di Anatomia Patologica, Istituto Tumori IRCCS "Giovanni Paolo II", Italy.
Valerio TavernitiInternational Agency for Research on Cancer, Lyon, France.
Maria Carmen Romero-MedinaInternational Agency for Research on Cancer, Lyon, France.
Luisa GalatiInternational Agency for Research on Cancer, Lyon, France.
Cecilia SirandInternational Agency for Research on Cancer, Lyon, France.
Naveed ShahzadSchool of Biological Sciences, University of the Punjab, Lahore, Pakistan.
Masahiro ShudaCancer Virology Program, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: mas253@pitt.edu.
Tarik GheitInternational Agency for Research on Cancer, Lyon, France. Electronic address: gheitt@iarc.who.in.
Rosita AccardiInternational Agency for Research on Cancer, Lyon, France.
Massimo TommasinoInternational Agency for Research on Cancer, Lyon, France.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA121973World Health Organization 001
6 · The paper itself

Abstract

Merkel Cell Carcinoma (MCC) is a rare neuroendocrine skin cancer. In our previous work, we decoded genes specifically deregulated by MCPyV early genes as opposed to other polyomaviruses and established functional importance of NDRG1 in inhibiting cellular proliferation and migration in MCC. In the present work, we found the SET protein, (I2PP2A, intrinsic inhibitor of PP2A) upstream of NDRG1 which was modulated by MCPyV early genes, both in hTERT-HK-MCPyV and MCPyV-positive (+) MCC cell lines. Additionally, MCC dermal tumour nodule tissues showed strong SET expression. Inhibition of the SET-PP2A interaction in hTERT-HK-MCPyV using the small molecule inhibitor, FTY720, increased NDRG1 expression and inhibited cell cycle regulators, cyclinD1 and CDK2. SET inhibition by shRNA and FTY720 also decreased cell proliferation and colony formation in MCPyV(+) MCC cells. Overall, these results pave a path for use of drugs targeting SET protein for the treatment of MCC.

Indexed as

Carcinoma, Merkel CellCell MovementCell ProliferationMerkel cell polyomavirusProtein Phosphatase 2Cell Cycle ProteinsCell Line, TumorCyclin-Dependent Kinase 2DNA-Binding ProteinsFingolimod HydrochlorideHistone ChaperonesHumansIntracellular Signaling Peptides and ProteinsN-myc Downstream-Regulated Gene 1 ProteinPolyomavirus InfectionsSkin NeoplasmsCDK2 protein, humanCell Cycle ProteinsCyclin-Dependent Kinase 2DNA-Binding ProteinsFingolimod HydrochlorideHistone ChaperonesIntracellular Signaling Peptides and ProteinsN-myc Downstream-Regulated Gene 1 ProteinProtein Phosphatase 2SET protein, humanTranscription FactorsFTY720Merkel Cell PolyomavirusNDRG1PP2ASET

Identifiers

PMID38917692
PMCPMC11552451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.